Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC
Condition: Locally Advanced Head and Neck Squamous Cell Carcinoma Intervention: Combination Product: Durvalumab + Tremelimumab + RT Sponsor: University of Erlangen-Nürnberg Medical School Not yet recruiting
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου